Navigation Links
BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
Date:1/3/2008

ming of decisions by regulatory authorities concerning marketing applications, labeling and pricing for Aldurazyme and manufacturing facilities to be used for Aldurazyme; the companies' ability to obtain and maintain adequate patent and other proprietary rights protection for Aldurazyme; and those factors detailed in BioMarin's and Genzyme's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2006 Annual Report on Form 10-K, as amended, the factors contained in BioMarin's reports on Form 8-K, and the factors discussed under the caption "Risk Factors" in Genzyme's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. Neither BioMarin nor Genzyme is under any obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R) is a registered trademark of BioMarin Pharmaceutical Inc.

Genzyme(R) is a registered trademark of Genzyme Corporation.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

All rights reserved.

Contact:

BioMarin Genzyme

Investors Investors

Eugenia Shen Sally Curley

(415) 506-6570 (617) 768-6140

Media Media

Susan Berg Maria Cantor

(415) 506-6594 (617) 768-6690


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
2. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
3. BioMarin to Present at the BioCentury NewsMakers Conference
4. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
5. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
6. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
7. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
8. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme Launches Cholestagel(R) in Europe
11. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014  Decision Resources Group finds that ... in the United States ... penetration will be the level of savings achievable ... expected lower cost to patients. Payers plan to ... their pricing expectations in order to encourage physician ...
(Date:7/30/2014)... 2014  Replikins Ltd. today released new data on ... Before the current outbreaks, the mean Ebola Reston gene ... between 1995 and 2002 was 1.1; the mean Replikin ... sixteen-fold in 2013, thus predicting the current outbreaks in ... been shown to be able to predict outbreaks (1). ...
(Date:7/30/2014)... AZ (PRWEB) July 30, 2014 Sales ... the launch of blended sales training programs for companies ... sales training programs used by thousands of salespeople over ... blended sales training program can be customized to address ... , The blended sales training program consists ...
(Date:7/30/2014)... NY (PRWEB) July 30, 2014 July ... (Twitter: @APDN), a biotechnology firm that provides DNA-based authentication ... E. Hogan, Ph.D. Vice President of Life Sciences, a ... , Dr. Hogan will lead APDN’s drive ... business relationships with biotech and healthcare customers, provide guidance ...
Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3
... Ash ... the company is in the initial phases of a multi-year $6 million expansion project ... located in Riverview, Michigan. Expansions will include a new reactor bay and warehouse. ... Detroit, MI (PRWEB) ...
... Sept. 30 InteKrin Therapeutics Inc. announced today positive results ... the 45th European Association for the Study of Diabetes ... data will be presented at 1:45 PM Friday, October 2, ... His presentation is entitled "Impact of INT131 Besylate, a ...
... September 30 , - 76% ... Glycemic Control Versus Lantus(R) , Sanofi-aventis ... of a,head-to-head study providing further evidence on the efficacy of ... insulin detemir. The study was presented during the 45th,Annual Meeting ...
Cached Biology Technology:Ash Stevens Plans $6 Million Facility Expansion to Bolster CMC Capabilities 2InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting 2Superior Efficacy-dose Ratio for Lantus(R) Over detemir 2Superior Efficacy-dose Ratio for Lantus(R) Over detemir 3Superior Efficacy-dose Ratio for Lantus(R) Over detemir 4Superior Efficacy-dose Ratio for Lantus(R) Over detemir 5
(Date:7/30/2014)... University,s College of Engineering recently received a $330,000 ... project, "Nanoparticle-directed synthesis of organic nanorods." , ... the creation and utilization of functional materials, devices, ... major bottleneck in scaling up nanotechnology is the ... materials into one device. A research team led ...
(Date:7/30/2014)... injury (SCI), traumatic brain injury (TBI) and peripheral nerve ... learned over the past 30 years regarding both the ... growth, but this large body of information has not ... his team from University of Miami in USA proposed ... consensus is emerging that one contributing factor is a ...
(Date:7/30/2014)... Washington, DCToday scientists unveiled the first high-resolution map ... the entire country of Per. The new and ... a sea change for future market-based carbon economies. ... extremely high ecological diversity and it provides the ... degradation for conservation, land use, and enforcement purposes. ...
Breaking Biology News(10 mins):NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... to promote interdisciplinary research that addresses complex interactions ... in recent years, but success is often elusive. ... social scientists attempting such work, Eric D. Roy ... a variety of institutions surveyed researchers at all ...
... MADISON, Wis. By any measure, tuberculosis (TB) is a wildly ... every corner of the world, with a new infection of a ... a new analysis of dozens of tuberculosis genomes gathered from around ... TB is so prevalent and how it evolves to resist countermeasures. ...
... August 2013 Metals such as iron, copper, and ... years, studies have shown that these nutritionally-essential metals are ... animal models of AD. Scientists are now exploring whether ... or are indicative of other ongoing pathologic processes. ...
Cached Biology News:Survey highlights barriers to interdisciplinary environmental science 2Tuberculosis genomes portray secrets of pathogen's success 2Elevated levels of copper in amyloid plaques associated with neurodegeneration in mouse models of AD 2
... (1995) This volume provides excellent ... for the study of major HIV proteins ... ribonuclease H, integrase and protease. Expression of ... Tat and Rev assays; HIV/CD4 interactions; transient ...
Monkey IL-2 ELISPOT Kit with white/opague microtiter plates...
Tachykinin (H-2)...
Human GATA-2 Affinity Purified Polyclonal Ab...
Biology Products: